Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

507 ARTÍCULOS , VIENDO DEL 1 AL 15

APOE ɛ2 is associated with white matter hyperintensity volume in CADASIL

Gesierich B, Opherk C, Rosand J, Gonik M, Malik R, Jouvent E, Hervé D, Adib-Samii P, Bevan S, Pianese L, Silvestri S, Dotti MT, De Stefano N, van der Grond J, Boon EM, Pescini F, Rost N, Pantoni L, Oberstein SA, Federico A, Ragno M, Markus HS, Tournier-Lasserve E, Chabriat H, Dichgans M, Duering M, Ewers M.

J Cereb Blood Flow Metab. 2016 Jan;36(1):199-203. doi: 10.1038/jcbfm.2015.85.

From Subjective Cognitive Complaints to Dementia: Who is at Risk?: A Systematic Review

Mendonça MD, Alves L, Bugalho P.

Am J Alzheimers Dis Other Demen. 2016 Mar;31(2):105-14. doi: 10.1177/1533317515592331.

The neuropathology and cerebrovascular mechanisms of dementia

Raz L, Knoefel J, Bhaskar K.

J Cereb Blood Flow Metab. 2016 Jan;36(1):172-86. doi: 10.1038/jcbfm.2015.164.

Gene Expression Studies on Human Trisomy 21 iPSCs and Neurons: Towards Mechanisms Underlying Down's Syndrome and Early Alzheimer's Disease-Like Pathologies

Weick JP, Kang H, Bonadurer GF 3rd, Bhattacharyya A.

Methods Mol Biol. 2016;1303:247-65. doi: 10.1007/978-1-4939-2627-5_15.

The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease

Iulita MF, Cuello AC.

Curr Alzheimer Res. 2016;13(1):53-67. doi: 10.2174/1567205012666150921100030.

Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy

Phillips C, Fahimi A, Das D, Mojabi FS, Ponnusamy R, Salehi A.

Curr Alzheimer Res. 2016;13(1):68-83. doi: 10.2174/1567205012666150921095924.

Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome

Hamlett ED, Boger HA, Ledreux A, Kelley CM, Mufson EJ, Falangola MF, Guilfoyle DN, Nixon RA, Patterson D, Duval N, Granholm AC.

Curr Alzheimer Res. 2016;13(1):35-52. doi: 10.2174/1567205012666150921095505.

[Cognitive rehabilitation in early stage Alzheimer's disease]

Kasper E, Thöne-Otto A, Bürger K, Schröder SG, Hoffmann W, Schneider W, Teipel S.

Nervenarzt. 2016 Jul;87(7):708-18. doi: 10.1007/s00115-015-4426-2.

Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome

Giulietti A, Vignini A, Nanetti L, Mazzanti L, Di Primio R, Salvolini E.

Curr Neuropharmacol. 2016;14(2):177-90. doi: 10.2174/1570159x13666150928155321.

Entorhinal cortex: a good biomarker of mild cognitive impairment and mild Alzheimer's disease

Zhou M, Zhang F, Zhao L, Qian J, Dong C.

Rev Neurosci. 2016 Feb;27(2):185-95. doi: 10.1515/revneuro-2015-0019.

Predictive factors for disease progression in patients with early-onset Alzheimer's disease

Yoon B, Shim YS, Park HK, Park SA, Choi SH, Yang DW.

J Alzheimers Dis. 2016;49(1):85-91. doi: 10.3233/JAD-150462.

The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective

Salehi A, Ashford JW, Mufson EJ.

Curr Alzheimer Res. 2016;13(1):2-6. doi: 10.2174/1567205012999151021102914.

Detection and Differentiation of Frontotemporal Dementia and Related Disorders From Alzheimer Disease Using the Montreal Cognitive Assessment

Coleman KK, Coleman BL, MacKinley JD, Pasternak SH, Finger EC.

Alzheimer Dis Assoc Disord. 2016 Jul-Sep;30(3):258-63. doi: 10.1097/WAD.0000000000000119.

Recent Updates on the Association Between Alzheimer's Disease and Vascular Dementia

Ashraf GM, Chibber S, Mohammad, Zaidi SK, Tabrez S, Ahmad A, Shakil S, Mushtaq G, Baeesa SS, Kamal MA.

Med Chem. 2016;12(3):226-37. doi: 10.2174/1573406411666151030111820.

Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia

Graff-Radford J, Josephs KA, Parisi JE, Dickson DW, Giannini C, Boeve BF.

JAMA Neurol. 2016 Jan;73(1):123-5. doi: 10.1001/jamaneurol.2015.2711.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias